Tech Company Financing Transactions
JenaValve Technology Funding Round
On 9/1/2022, JenaValve Technology raised $100 million in Series C funding from Bain Capital Life Sciences, Andera Partners and Cormorant Asset Management.
Transaction Overview
Company Name
Announced On
9/1/2022
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to complete its investigational device exemption (IDE) premarket approval (PMA) study to obtain FDA approval for its Trilogy Heart Valve System, a treatment for high surgical risk patients with symptomatic, severe aortic regurgitation (AR).
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
7545 Irvine Center Dr. 100
Irvine, CA 92618
USA
Irvine, CA 92618
USA
Phone
Website
Email Address
Overview
In 2006 the company was founded to develop second generation transcatheter aortic valve replacement (TAVR) systems for transapical and transfemoral implantation.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Kilcoyne
Chief Financial Officer
Peter Wulff
VP - Operations
Jeff Thiel
VP - R & D
Greg Mirigian
VP - Regulatory Affairs
Janet Fauls
VP - Regulatory Affairs
Vinny Podichetty
Browse more venture capital transactions:
Prev: 8/31/2022: Wreno venture capital transaction
Next: 9/1/2022: Lithosphere venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs